How Casgevy Works for Sickle Cell Disease
Casgevy (exagamglogene autotemcel) treats sickle cell disease (SCD) through CRISPR-Cas9 gene editing. Doctors extract a patient's hematopoietic stem cells from blood, edit their BCL11A gene in a lab to boost fetal hemoglobin (HbF) production, then infuse the modified cells back after chemotherapy clears out the originals. This corrects the root cause—mutated adult hemoglobin (HbS) that polymerizes under low oxygen, distorting red blood cells into sickle shapes, which block blood flow and cause pain crises, organ damage, and anemia.[1][2]
Elevated HbF interferes with HbS polymerization, producing mostly normal-shaped red blood cells that carry oxygen effectively and resist sickling.
Does It Cure Sickle Cell or Just Manage Symptoms?
Casgevy aims for a one-time functional cure. In trials like City of Hope phase 1/2, 29/31 patients (94%) with severe SCD achieved freedom from vaso-occlusive crises for at least 12 months post-infusion. Nearly all eliminated severe anemia, with average HbF at 30-40% long-term. No further crises or transfusions needed in responders, unlike lifelong symptom management with hydroxyurea or transfusions.[2][3]
Step-by-Step Treatment Process
1. Stem Cell Collection: Patient gets growth factor shots to mobilize stem cells, collected via apheresis (4-6 hours).
2. Gene Editing: Cells edited with CRISPR to disrupt BCL11A enhancer, increasing HbF without altering other genes.
3. Chemotherapy Conditioning: High-dose chemo (like busulfan) wipes out bone marrow over 3-4 days.
4. Infusion and Recovery: Edited cells infused; engraftment takes 3-4 weeks. Hospital stay: 4-6 weeks; full recovery 6 months.
5. Monitoring: Lifelong follow-up for HbF levels and complications.
Total timeline: 6-12 months from start to engraftment.[1][4]
How Effective Are Trial Results?
In KREWE phase 3 (32 patients), 96% resolved severe vaso-occlusive events; 93% transfusion-independent at 12 months. Phase 1/2 data (up to 5+ years) shows sustained benefits in 42/44 patients. FDA/EMA approved in 2023/2024 for ages 12+ with recurrent crises or history of transfusions.[2][3]
Real-world caveats: Not all respond (rare non-engraftment); benefits may wane if edited cells decline.
Common Side Effects and Risks
Most risks from chemotherapy: infertility (90%+), infections, low blood counts (resolved in weeks). Gene editing side effects minimal—no CRISPR-related cancers in trials to date. Long-term: potential leukemia risk under study. Patients report fatigue, nausea, mouth sores during conditioning.[1][4]
Cost and Who Pays for Casgevy?
List price: $2.2 million per treatment (US). No patent expiry data yet (Vertex/CRISPR Therapeutics hold exclusivities to 2038+). Coverage expanding via Medicaid, some insurers; financial assistance programs exist.[5]
Casgevy vs. Other Sickle Cell Treatments
| Treatment | Mechanism | Duration | Cost | Cure Potential |
|-----------|-----------|----------|------|---------------|
| Casgevy | Gene edit boosts HbF | One-time | $2.2M | Functional cure in ~90% |
| Hydroxyurea | Raises HbF chemically | Daily pill | $100/month | Symptom control |
| Voxelotor | Improves HbS oxygen binding | Daily pill | $100K/year | Mild benefit |
| Crizanlizumab | Blocks cell sticking | Monthly IV | $100K/year | Reduces crises 45% |
| LentiGlobin (Zynteglo, beta-thal only) | Lentiviral gene addition | One-time | $2.8M | Similar cure rate |
Casgevy edges out with higher, durable response rates but requires chemo.[2][6]
Sources
[1]: FDA Casgevy Label
[2]: NEJM: City of Hope Trial
[3]: Vertex Phase 3 Data
[4]: Casgevy HCP Site
[5]: DrugPatentWatch: Casgevy Patents
[6]: NEJM: LentiGlobin